A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLL
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Acalabrutinib (Primary) ; Obinutuzumab
- Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Acerta Pharma
- 02 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 23 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 27 Nov 2014 New trial record